Latest Breaking News On - Amy perrin ross - Page 1 : comparemela.com

DMTs in Aging MS Patients: When and How to Stop

Natalizumab-sztn Receives FDA Approval as First Biosimilar for Multiple Sclerosis

The approval was based on evidence showing no clinically meaningful differences between natalizumab-sztn and the reference drug in terms of safety, purity, and potency.

Neuromyelitis Optica: What You Need to Know Now and in the Future

Novartis study: Nurses and MS patients give thumbs-up to Kesimpta for ease of use

Mar 3, 2021 9:55am Novartis presented positive study data at the sixth annual Americas Committee for Treatment and Research in Multiple Sclerosis Forum from nurses and patients using its Kesimpta auto-injector pen for MS. (Novartis) Novartis nabbed FDA approval for Kesimpta to treat multiple sclerosis last year, but now it’s getting the thumbs-up from MS patients and nurses. Novartis presented study data at the sixth annual Americas Committee for Treatment and Research in Multiple Sclerosis Forum in late February showing 84% preferred Kesimpta’s self-administration injector pen over rival administration methods. The kudos from a small, 130-participant study come as Novartis bids to make Kesimpta a first-treatment option. Kesimpta’s chief rival Roche’s Ocrevus, which also works by targeting CD20-expressing B-cells is an infusion treatment.

Survey: MS Patients, Nurses Prefer Sensoready Pen for Injecting Kesimpta

4.6 (9) People with multiple sclerosis (MS) and their nurses prefer the Sensoready autoinjector pen for subcutaneous self-administration of Kesimpta (ofatumumab) over other methods for injecting treatments, according to a survey. The survey was conducted by Novartis, which markets Kesimpta. Full findings from the survey will be presented at the 2021 Americas Committee for Treatment and Research in Multiple Sclerosis Forum (ACTRIMS), taking place virtually Feb. 25–27. “For people living with a chronic disease such as MS, access to highly effective treatments and maintaining flexibility in their lives is paramount,” Estelle Vester-Blokland, MD, global head neuroscience medical affairs, Novartis Pharmaceuticals, said in a press release.